Clinical trials
Autoimmune Diseases of the Nervous System clinical trials
Below are recruiting autoimmune diseases of the nervous system clinical trials, each written for real people, not researchers. We’re tracking 83 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05474378RecruitingPhase 1
CAR T cell therapy for recurrent glioblastoma
This early-phase study tests a type of immune-cell treatment (CAR T cells) aimed at a target called B7-H3 in people with glioblastoma or related grade 4 brain tumors that have come back. It’s meant to see if the treatment can shrink the tumor or control the disease and to learn how safe it is.
Palo Alto, CaliforniaAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT04830137RecruitingPhase 1
Test drug NX-2127 for hard-to-treat B-cell blood cancers
This Phase 1 trial tests the safety and early effectiveness of NX-2127 in adults with relapsed or refractory B-cell cancers. If you qualify, you may receive a new targeted treatment because your cancer has returned or not responded to prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT07456358Recruiting
Immune attack targets in brain disease
This study looks at the immune system's role in neurological problems caused by cancer immunotherapy or autoimmune diseases. Researchers will collect spinal fluid to find out which immune targets are involved, which may help improve diagnosis and treatment.
Le Kremlin-BicêtreAges 18 years+ - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Newport Beach, CaliforniaAges 18–75 - NCT03872102Recruiting
Brain imaging study to track Parkinson-related disease changes
This study uses brain scans and clinical check-ins to better diagnose and predict how Parkinson-related conditions may progress over time. It may help researchers find markers that explain why symptoms change, and could improve future care.
Dallas, TexasAges Any age - NCT07148791RecruitingPhase 2
CAR-T therapy for relapsed or refractory IgG4-related disease
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
Beijing, Beijing MunicipalityAges 18–75 - NCT06826430RecruitingPhase 1
CAR-T cell therapy for severe lupus-related low platelets
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Beijing, Beijing MunicipalityAges 18–70 - NCT06778382RecruitingPhase 2
Delaying treatment after destroying lung spots from colorectal cancer
This trial tests if it's safe to wait before starting full-body therapy after treating a small number of lung tumors (5 or fewer) in people whose colorectal cancer had been gone for at least 6 months. You would first get local treatments like surgery or radiation to destroy the lung spots, then delay additional cancer drugs to see how you do.
Jinan, ShandongAges 18–75 - NCT06733610RecruitingPhase 1
CAR T-cell therapy for AIHA after 3 failed treatments
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Autoimmune Diseases of the Nervous System trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune diseases of the nervous system?
- Yes. Clin2 currently lists 83 recruiting autoimmune diseases of the nervous system studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune diseases of the nervous system trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune diseases of the nervous system trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.